Celyad Oncology SA is a biotechnology company focused on the discovery and development of innovative technologies chimeric antigen receptor (CAR) T-cell therapies. The company is focusing on opportunities to fully harness the true potential of its proprietary technology platforms and intellectual property and support the development of next-generation CAR T candidates in solid tumors and hematological malignancies.

Employees

Sector

Biotechnology & Medical Research

Calendar

23/09 Earnings release - Q2 2026

More about the company

Market Cap	1.17Cr 1.36Cr 1.1Cr 1Cr 1.88Cr 129.11Cr 1.89Cr 13Cr 5.06Cr 65Cr 5.09Cr 4.98Cr 216.77Cr	P/E 2024	-5.06x	P/E 2025	9.44x
Enterprise Value	99.75L 1.16Cr 93.66L 85.5L 1.61Cr 110.23Cr 1.62Cr 11Cr 4.32Cr 56Cr 4.35Cr 4.26Cr 185.08Cr	EV / Sales 2024	141x	EV / Sales 2025	281x
Free-Float	34.3%	Yield 2024 *	-	Yield 2025	-

14/07	Celyad Oncology SA announced that it expects to receive ?0.5 million in funding from Fortress Investment Group LLC	CI
14/07	Celyad Oncology to Raise Funds via Private Placement	MT
15/04	Prelude Therapeutics Incorporated Appoints Charles Morris as Chief Medical Officer, Effective April 20, 2026	CI
02/04	Celyad Oncology SA Reports Earnings Results for the Full Year Ended December 31, 2025	CI
30/25/30	Celyad Oncology to Sell Belgian Research Facility for EUR3 Million	MT
29/25/29	Celyad Oncology announces research facility divestiture	RE
29/25/29	An undisclosed buyer agreed to acquire Research facility?s equipment and office furniture in Mont-Saint-Guibert, Belgium of Celyad Oncology SA for ?3 million.	CI
25/25/25	Celyad Oncology SA Reports Earnings Results for the Half Year Ended June 30, 2025	CI
26/25/26	Celyad Oncology Announces Discontinuation of R&D Activities and Workforce	CI
29/25/29	Celyad Oncology to Receive EUR1 Million Capital Injection from Shareholder	MT
28/25/28	Celyad Oncology SA announced that it expects to receive ?1 million in funding from CFIP CLYD (UK) Limited	CI
25/25/25	Celyad Oncology Begins Strategic Review Amid Limited Financial Runway	MT
24/25/24	Celyad Oncology Announces Strategic Review	CI

28/22/28	HC Wainwright Downgrades Celyad Oncology Neutral From Buy, Shares Plunge 12% at Midday Trading	MT
11/22/11	Wells Fargo Adjusts Celyad Oncology's Price Target to $11 from $20, Keeps Overweight Rating	MT
06/21/06	Celyad Oncology : HC Wainwright Adjusts Celyad Oncology's Price Target to $15 From $17, Maintains Buy Rating	MT
26/21/26	Celyad Oncology : JonesTrading Downgrades Celyad Oncology to Hold from Buy	MT
08/20/08	Celyad Oncology : HC Wainwright Adjusts Celyad Oncology's Price Target to $18 From $22, Keeps Buy Rating	MT

29/07	Celyad Oncology : Publication of a transparency notification received from Tolefi SA (Article 14§1 of the Law of 2 May 2007)	PU
14/07	Celyad Oncology : Announces €500,000 Private Placement	PU
20/05	Celyad Oncology : AGM Minutes - informal translation EN	PU
02/04	Celyad Oncology : reports full year 2025 financial results and business highlights	PU
29/25/29	Celyad Oncology : Announces Research Facility Divestiture	PU

29/07	Celyad Oncology : Publication d’une notification de transparence reçue de Tolefi SA (Article 14§1 de la Loi du 2 Mai 2007)
18/07	Rustige start cijferseizoen in Brussel
14/07	Celyad kondigt private plaatsing van 500.000 euro aan
20/05	Celyad Oncology : AGO Procès Verbal - version FR
17/04	Celyad Oncology : Rapport Annuel 2025 FR

Celyad SA Share Price Other OTC

Stocks

CLYYF

BE0974260896

Biotechnology & Medical Research

Valuation : Celyad SA

Latest news : Celyad SA

Analysts' recommendations : Celyad SA

Press Releases : Celyad SA

News in other languages : Celyad SA

Quotes and Performance

Managers and Directors : Celyad SA

Other Biotechnology & Medical Research

Financials

Company Profile

Manager	Title	Age	Since
David Georges DFI	Director of Finance/CFO	-	01/01/2019
An Phan LAW	General Counsel	51	01/09/2021

Director	Title	Age	Since
Michel Lussier CHM	Chairman	69	24/07/2007
Serge Goblet BRD	Director/Board Member	-	01/01/2008
Hilde Windels CHM	Chairman	61	23/06/2022

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CELYAD SA	-25.25%	-.--%	-	-	1.36Cr
LONZA GROUP AG	-0.14%	-2.21%	+0.67%	+17.57%	4.98TCr
REVOLUTION MEDICINES, INC.	+0.56%	-2.70%	+420.31%	+486.82%	4.41TCr
IQVIA HOLDINGS INC.	-0.62%	+0.38%	+41.73%	+16.08%	4.3TCr
BEONE MEDICINES AG	-0.22%	-4.82%	+7.88%	+71.46%	4.09TCr
CELLTRION, INC.	-0.94%	-1.77%	+18.34%	+46.84%	3.31TCr
MEDPACE HOLDINGS, INC.	-1.34%	-4.66%	+23.68%	+114.05%	1.66TCr
ASCENDIS PHARMA A/S	-0.28%	+3.31%	-	-	1.73TCr
EUROFINS SCIENTIFIC SE	-0.61%	-2.65%	+10.99%	+27.33%	1.46TCr
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-0.12%	-3.15%	+78.76%	+37.51%	1.38TCr
Average	-2.89%	-1.37%	+75.30%	+102.21%	3.03TCr
Weighted average by Cap.	-0.29%	-1.50%	+89.57%	+118.42%

	2024	2025
Net sales	2L 2L 2L 2L 3L 2.06Cr 3L 20.7L 8L 1.04Cr 8L 8L 3.45Cr	21T 24.39T 19.72T 18T 33.81T 23.21L 34.06T 2L 90.91T 11.77L 91.58T 89.59T 38.97L
Net income	-58.24L -67.64L -54.69L -49.92L -93.78L -64Cr -94.45L -6.48Cr -2.52Cr -33Cr -2.54Cr -2.48Cr -108.06Cr	8L 10L 8L 7L 13.36L 9.17Cr 13.46L 92.35L 35.93L 4.65Cr 36.2L 35.41L 15Cr
Net Debt	-32.95L -38.27L -30.94L -28.24L -53.06L -36Cr -53.44L -3.67Cr -1.43Cr -18Cr -1.44Cr -1.41Cr -61Cr	-17.08L -19.84L -16.04L -14.64L -27.5L -19Cr -27.7L -1.9Cr -73.94L -9.57Cr -74.48L -72.86L -32Cr